Skip to main content
. 2014 Jun 21;20(23):7442–7451. doi: 10.3748/wjg.v20.i23.7442

Figure 6.

Figure 6

Graft tumor necrosis factor-α, interferon-γ, interleukin-10, and transforming growth factor-β levels. Graft tumor necrosis factor-α (TNF-α), interferon-γ (INF-γ), interleukin-10 (IL-10), and transforming growth factor-β (TGF-β) levels in group B were significantly decreased compared to that in group A at day 7 (17.2128 ± 0.4991 vs 12.8364 ± 0.7131, P < 0.05; 810.2637 ± 25.1175 vs 555.3763 ± 17.9702, P < 0.05; 80.3756 ± 2.5866 vs 59.9878 ± 2.1521, P < 0.05; 130.8756 ± 3.3428 vs 109.9878 ± 9.7968, P < 0.05). Graft TNF-α and IFN-γ levels in group C were significantly decreased compared to that in group B at day 7 (10.6473 ± 0.0710 vs 17.2128 ± 0.4991, P < 0.05; 545.1506 ± 31.9416 vs 810.2637 ± 25.1175, P < 0.05); graft IL-10 and TGF-β levels in group C were significantly increased compared to that in group B at day 7 (125.7773 ± 4.7719 vs 80.3756 ± 2.5866, P < 0.05; 234.5273 ± 9.3980 vs 545.1506 ± 31.9416, P < 0.05). A: Group A (non-rejection); B: Group B (rejection); C: Group C (BM MSC therapy). All values are mean ± SD (n = 6). aP < 0.05 vs group B.